Harnessing AI for enhanced evidence-based laboratory medicine (EBLM)

IF 2.9 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Clinica Chimica Acta Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.cca.2025.120181
Tahir S. Pillay , Deniz İlhan Topcu , Sedef Yenice
{"title":"Harnessing AI for enhanced evidence-based laboratory medicine (EBLM)","authors":"Tahir S. Pillay ,&nbsp;Deniz İlhan Topcu ,&nbsp;Sedef Yenice","doi":"10.1016/j.cca.2025.120181","DOIUrl":null,"url":null,"abstract":"<div><div>The integration of artificial intelligence (AI) into laboratory medicine, is revolutionizing diagnostic accuracy, operational efficiency, and personalized patient care. AI technologies(machine learning, natural language processing and computer vision) advance evidence-based laboratory medicine (EBLM) by automating and optimizing critical processes(formulating clinical questions, conducting literature searches, appraising evidence, and developing clinical guidelines). These reduce the time for systematic reviews, ensuring consistency in appraisal, and enabling real-time updates to guidelines. AI supports personalized medicine by analyzing large datasets, genetic information and electronic health records (EHRs), to tailor diagnostic and treatment plans to patient profiles. Predictive analytics enhance outcomes by leveraging historical data and ongoing monitoring to predict responses and optimize care pathways. Despite the transformative potential, there are challenges. The accuracy, transparency, and explainability of AI algorithms is critical for gaining trust and ensuring ethical deployment. Integration into existing clinical workflows requires collaboration between AI developers and users to ensure seamless user-friendly adoption. Ethical considerations, such as privacy,data security, and algorithmic bias, must also be addressed to mitigate risks and ensure equitable healthcare delivery. Regulatory frameworks, eg. The EU AI Regulation, emphasize transparency, data governance, and human oversight, particularly for high-risk AI systems. The economic and operational benefits are cost savings, improved diagnostic precision, and enhanced patient outcomes. Future trends (federated learning and self-supervised learning), will enhance the scalability and applicability of AI in EBLM, paving the way for a new era of precision medicine. AI in EBLM has the potential to transform healthcare delivery, improve patient outcomes, and advance personalized/precision medicine.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120181"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125000609","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The integration of artificial intelligence (AI) into laboratory medicine, is revolutionizing diagnostic accuracy, operational efficiency, and personalized patient care. AI technologies(machine learning, natural language processing and computer vision) advance evidence-based laboratory medicine (EBLM) by automating and optimizing critical processes(formulating clinical questions, conducting literature searches, appraising evidence, and developing clinical guidelines). These reduce the time for systematic reviews, ensuring consistency in appraisal, and enabling real-time updates to guidelines. AI supports personalized medicine by analyzing large datasets, genetic information and electronic health records (EHRs), to tailor diagnostic and treatment plans to patient profiles. Predictive analytics enhance outcomes by leveraging historical data and ongoing monitoring to predict responses and optimize care pathways. Despite the transformative potential, there are challenges. The accuracy, transparency, and explainability of AI algorithms is critical for gaining trust and ensuring ethical deployment. Integration into existing clinical workflows requires collaboration between AI developers and users to ensure seamless user-friendly adoption. Ethical considerations, such as privacy,data security, and algorithmic bias, must also be addressed to mitigate risks and ensure equitable healthcare delivery. Regulatory frameworks, eg. The EU AI Regulation, emphasize transparency, data governance, and human oversight, particularly for high-risk AI systems. The economic and operational benefits are cost savings, improved diagnostic precision, and enhanced patient outcomes. Future trends (federated learning and self-supervised learning), will enhance the scalability and applicability of AI in EBLM, paving the way for a new era of precision medicine. AI in EBLM has the potential to transform healthcare delivery, improve patient outcomes, and advance personalized/precision medicine.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用AI加强循证检验医学(EBLM)。
将人工智能(AI)整合到实验室医学中,正在彻底改变诊断准确性、操作效率和个性化患者护理。人工智能技术(机器学习、自然语言处理和计算机视觉)通过自动化和优化关键流程(制定临床问题、进行文献检索、评估证据和制定临床指南)来推进循证检验医学(EBLM)。这减少了系统审查的时间,确保了评估的一致性,并使指导方针能够实时更新。人工智能通过分析大型数据集、遗传信息和电子健康记录(EHRs)来支持个性化医疗,从而根据患者的情况量身定制诊断和治疗计划。预测分析通过利用历史数据和持续监测来预测反应和优化护理途径,从而提高结果。尽管具有变革潜力,但也存在挑战。人工智能算法的准确性、透明度和可解释性对于获得信任和确保道德部署至关重要。集成到现有的临床工作流程中需要人工智能开发人员和用户之间的协作,以确保无缝的用户友好采用。还必须解决隐私、数据安全和算法偏差等道德问题,以减轻风险并确保公平的医疗保健服务。监管框架,如:欧盟人工智能法规强调透明度、数据治理和人类监督,特别是对于高风险的人工智能系统。经济和操作上的好处是节省了成本,提高了诊断精度,并改善了患者的预后。未来的趋势(联邦学习和自我监督学习)将增强人工智能在EBLM中的可扩展性和适用性,为精准医疗的新时代铺平道路。EBLM中的人工智能有可能改变医疗保健服务,改善患者的治疗效果,并推进个性化/精准医疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinica Chimica Acta
Clinica Chimica Acta 医学-医学实验技术
CiteScore
10.10
自引率
2.00%
发文量
1268
审稿时长
23 days
期刊介绍: The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
期刊最新文献
A laboratory-driven clinical decision support system algorithm for personalized and automated cardiovascular risk stratification in primary care patients. Population-specific reference intervals for 22 biochemical analytes: three indirect methods application in a multi-ethnic area Resolving a complex GPIHBP1 exons 3–4 deletion adjacent to low-complexity repeats using adaptive sampling long-read sequencing in familial chylomicronaemia From bench to bedside: translating the histone deacetylase inhibitors into prostate cancer therapies Targeted next-generation sequencing in diagnosing reproductive tract infections: a comparative study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1